Studying Fentanyl in Patients With Cancer

• Status: Terminated
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Studying blood samples from cancer patients undergoing pain treatment in the laboratory may help doctors learn more about how pain drugs work in the body. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study is looking at fentanyl in patients with cancer.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Collaborator: National Cancer Institute (NCI)
• Treatments: Citric Acid; Fentanyl

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of cancer

• Inpatient at the Johns Hopkins Hospital Cancer Center undergoing pain treatment with continuous infusion fentanyl citrate for ≥ 5 days

PATIENT CHARACTERISTICS:

• Willing to change to an alternative opioid

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• At least 72 hours since transdermal fentanyl citrate administration

• At least 12 hours since transmucosal fentanyl citrate administration

• No known requirement for continued opioid therapy with any fentanyl citrate products after discontinuation of fentanyl citrate therapy